Nanogen Subsidiary SynX Signs on Five European Distributors

Nanogen’s subsidiary SynX has signed on five European distributors for its point-of-care diagnostics products, Nanogen said this week.

The new distributors, which Nanogen did not name, expand SynX’s coverage to 28 European countries.

They will distribute and market SynX’s point-of-care tests and research products for congestive heart failure and myocardial infarction.

SynX said its CHF diagnostic test is expected to launch this year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A genome-wide association study highlights a potential role for hair follicles in acne risk, according to New Scientist.

Newsday reports that breast cancer genetic testing guidelines for are out of date and may miss individuals.

In Cell this week: gene editing-based strategy to screen for immune system regulators, ancient plague patterns, and more.

Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.